FDA Clears Becton Dickinson’s Next-Gen Biopsy System Bolstering IHI’s 4.44% Stake
Becton, Dickinson secured FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy System, set for launch in early 2026. With Becton, Dickinson representing 4.44% of the iShares US Medical Devices ETF, this approval could materially influence IHI’s performance.
Related News
ENHA
Enhanced Trial Shifts to Five-Year Monitoring After 91% Athlete Testosterone Use
ENHA•
SHEL
Shell ex-dividend cuts FTSE 100 by 6.84 points
SHEL•
EQNR
Equinor Sells 19% Ringvei Vest Stakes, Increases Wisting to 42.5% for $23M
EQNR•
VBCJ
Vanguard BondBuilder Corporate ETFs amass $242M, boosting segment to $70B
VBCJ•
INTU
Intuit to Launch AI-Driven Platforms in August, Cuts 17% Workforce to Fund Growth
INTU•
Sources
BB